J&J's Ottava Clears the FDA: What a New Robotic Platform Means for Surgical Practice
On July 22, 2026, the FDA granted Johnson & Johnson's OTTAVA Robotic Surgical System De Novo authorization for ten upper-abdominal general surgery procedures, including gastric bypass, gastrectomy, cholecystectomy, appendectomy, and hiatal hernia repair. It is the first table-integrated soft-tissue robotic platform to reach the U.S. market and the first genuine regulatory challenger to Intuitive Surgical's two-and-a-half-decade hold on the category — though Intuitive's installed base of 11,710 da Vinci systems, growing 12% year over year, dwarfs OTTAVA's current base of zero. The clearance also establishes a new device classification that may open a regulatory pathway for future table-integrated entrants.
Advancements in Laparoscopy and Robotic Surgery, this quarter's issue of Surgical Clinics (Meara & Duke, eds., Elsevier), was commissioned for exactly this moment. Its second chapter, on integrating artificial intelligence and technology into surgical practice, and its coverage of foregut, bariatric, and colorectal technique, give surgical departments a peer-reviewed reference for evaluating what a multi-platform robotic landscape means for procedure selection, training, and OR workflow — rather than relying on vendor literature alone.
Three uses stand out as departments respond to a widening field of robotic platforms. First, surgical chairs and OR committees comparing platforms for upcoming capital purchases can use Chapter 2's technology-integration review as independent context alongside vendor demonstrations. Second, bariatric and foregut surgery teams — among the first procedure categories OTTAVA was cleared for — can cross-reference Chapters 5 and 6 on foregut innovation and bariatric complication management when evaluating a new platform's procedure fit. Third, residency and fellowship programs can use the full issue as a current teaching reference for trainees who will increasingly encounter more than one robotic system during training.
For surgical department and academic medical libraries, this issue is a compact way to keep a collection current through a period of real platform change, without waiting for the next full textbook edition to catch up with a fast-moving regulatory and competitive landscape.
CLNZ Books sources this title directly from Elsevier, ships worldwide with secure card and PayPal payment, and offers institutional invoicing for library and departmental orders — the same sourcing and support behind every title in our Medicine collection.
Q&A
What did the FDA clear for robotic surgery in July 2026?
J&J's OTTAVA Robotic Surgical System received De Novo authorization for ten upper-abdominal general surgery procedures, including gastric bypass, gastrectomy, cholecystectomy, appendectomy, and hiatal hernia repair — the first table-integrated soft-tissue robotic platform cleared in the U.S.
Does this book cover the new wave of competing robotic platforms?
Yes. Chapter 2 is dedicated to integrating artificial intelligence and technology into surgical practice, giving departments a peer-reviewed reference point as more robotic platforms enter the market.
What procedures does Ottava's clearance cover, and does the book address those specialties?
Ottava is currently cleared for upper-abdominal procedures such as gastric bypass and gastrectomy; the book's Chapter 5 (foregut surgery) and Chapter 6 (bariatric surgery) cover the clinical and technical considerations in exactly those areas.
Is this issue useful for surgical training programs?
Yes. Its eleven practice-oriented reviews make it a current teaching reference for residents and fellows who will train across more than one robotic platform as the field diversifies.
Where can I buy Advancements in Laparoscopy and Robotic Surgery?
You can order it directly from CLNZ Books, with worldwide shipping included and secure payment via credit card or PayPal.
